A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
Latest Information Update: 27 May 2025
At a glance
- Drugs Axatilimab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 20 May 2025 Planned End Date changed from 15 Apr 2030 to 5 May 2030.
- 20 May 2025 Planned primary completion date changed from 15 Apr 2030 to 5 May 2030.
- 20 May 2025 Status changed from not yet recruiting to recruiting.